Last updated on: 09/06/2020
Name of organisation
1) Department/Research group
2) Organisation/affiliationEPID Research Oy
Short Name in the inventoryEPID Research
Administrative Contact
Title Dr
Last name ENCePP IQVIA Nordics Coordinator
First name -
Address line 1EPID Research Oy
Address line 2Metsänneidonkuja 6
Address line 3
CityEspoo
Postcode02130
CountryFinland
Phone number (incl. country code)358-40-8643912
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Dr
Last name Hoti
First name Fabian
Address line 1EPID Research Oy
Address line 2Metsänneidonkuja 6
Address line 3
CityEspoo
Postcode02130
CountryFinland
Phone number (incl. country code)358-40-5391919
Alternative phone number
Fax number (incl. country code)
2. Description
EPID Research is a scientific contract research organisation providing Real-World Evidence (RWE) studies. EPID Research is a fully owned subsidiary of StatFinn, and both companies are fully owned by IQVIA Ltd. We specialize in high quality pharmacoepidemiological research. We utilize Real-World Data from various health registries with patient-level information on drug prescriptions, diagnoses, treatments and outcomes. We provide for example feasibility studies, post-authorization safety studies, drug utilization studies and relative effectiveness studies. Our methodology combines clinical, pharmacological, epidemiological and statistical knowledge.
3. Category
For profit organisation
4. Available resources
In houseVia Contacts/Network
Programmers
Yes
No
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Congenital Malformations
Disorders of the central nervous system
Endocrine disorders
Gynaecology
Malignant disease
Osteoporosis
Pregnancy
Psychiatry
Respiratory diseases
Urinary tract disorders
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Less than 5
Number of patients/respondents involved in the study(ies)
Between 1500 and 14999
8. Access to data collection resources
Capacity to conduct face-to-face interviews
No
Electronic data capture systems
Yes
System used:
National Health Care Registers
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Nordic Patient Registers15
Nordic Population Registers9
Nordic Prescription Registers17
Nordic Causes of Death Registers11
Nordic Cancer Registers6
11. Registries established by centre
None
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
None
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
No
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Korhonen P, Heintjes E M, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ 2016;354:i3903.http://www.bmj.com/content/354/bmj.i3903.full
Tiihonen J, Lehti M, Aaltonen M, Kivivuori J, Kautiainen H, Virta L, Hoti F, Tanskanen A, Korhonen P. Psychotropic drugs and homicide: a prospective cohort study from Finland. World Psychiatry. 2015 Jun;14(2):245-7.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471985/
Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola S. Coronary heart disease mortality and hormone therapy before and after the women's health initiative. Obstet Gynecol. 2014; 124:947-953.http://www.ncbi.nlm.nih.gov/pubmed/25437723
